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1. Introduction
1.1. Prevalence and Incidence of Diabetes in Ontario, Canada
The scale of the problem of diabetes in family practice is described with respect to prevalence and incidence
in family medicine.
Type 2 diabetes (T2DM) and prediabetes [impaired fasting glucose (IFG); impaired glucose
tolerance (IGT); and / or both IFG and IGT] are common metabolic disturbances in Canada
and worldwide, having long been recognized to be reaching close to epidemic proportions [1].
Indeed, the global prevalence of diabetes in 2011 was 8.3% [2]. According to the National
Diabetes Surveillance System, in 2009, over 2 million Canadians were estimated to have T2DM;
a prevalence of T2DM 6.4% [3]. As many as one in six people over the age of 65 years are
currently estimated to have diabetes [4]. Adults from lower income groups are twice as likely
to have diabetes as those in the highest income groups [4]. Estimates suggest that over 5 million
Canadians had prediabetes in 2004; a prevalence of 23% for ages 40 to 74 years [5]. The
prevalence of IFG is more frequent in women but both IFG and IGT increase in prevalence
with age [6].
2. Predicted increase in numbers of people with diabetes
Alarmingly, diabetes prevalence is expected to increase significantly; this will be described in detail with
respect to the effect on the primary care system.
The global prevalence for diabetes is predicted to be 9.9% in 2030, an increase of approxi‐
mately 20% in 20 years [2]. Indeed, over time, the prevalence of Type 2 Diabetes (T2DM)
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in Ontario has increased at a much faster rate than anticipated. Adult diabetes prevalence
in Ontario rose by 80%, from 5% in 1995, to 9% in 2005[6], thereby exceeding the global
prevalence increase of T2DM of 6.4% projected for 2030 [7]. Following that, over a 6 year
period, a 31% increase in yearly incidence occurred in Canada, from 6.6 per 1,000 in 1997
to 8.2 per 1,000 in 2003 [7]. The diabetes epidemic is not restricted to Canada, as 1 in 10
adults in the USA now have diabetes [8].
Increasing numbers of people with diabetes will result in more healthcare resources being
utilised [5,6,7]. Current estimates suggest that people with diabetes use five-times as many
health resources as those without [9]. Therefore, developing and testing effective strategies to
increase detection of diabetes in the community is an important primary care and population
health issue. Furthermore, up to one third of the people with diabetes are estimated to be
undiagnosed [8,10] and may be developing diabetes-related complications which may also
remain undiagnosed. Not only will the utilisation of healthcare resources be restricted to
diabetes-related micro and macro vascular diseases, but other conditions as well. People with
diabetes or dysglycemia are at over a twofold risk of developing cardiovascular disease
compared to diabetes-free individuals [11,12,13]. These factors point to the seriousness of the
diabetes epidemic and its potential impact.
3. Progression of prediabetes to diabetes
The speed at which prediabetes progresses to diabetes has serious implications for adequate healthcare.
The scale of this will be discussed in depth.
Individuals with prediabetes are estimated to progress to type 2 diabetes at a rate of 10-12%
per year; in total up to as much as 70% will progress [14-16]. Furthermore, individuals with
both IFG and IGT develop type 2 diabetes at approximately twice the rate as those who have
only one of these impairments [17]. The speed at which prediabetes progresses to diabetes has
serious implications for adequate healthcare provision to the adult Canadian population aged
40 and over (which represented approximately 50% of the Canadian population in the 2006
census) [18].
Since diabetes is a multi-system metabolic chronic disorder, it causes complications that affect
many organs including eyes, nerves and kidneys as well as other health related consequences.
Specific complications of diabetes include macrovascular (i.e. coronary artery disease), and
microvascular (i.e. renal damage, nerve damage and retinal damage) [19]. Treatment for
diabetes consists of dietary and lifestyle changes, oral medication and injected insulin [19]. The
healthcare system will be stretched having to care for an epidemic of people with diabetic
complications.
However, pharmacological and lifestyle interventions could prevent or delay T2DM and thus
decrease morbidity and mortality associated with its complications if individuals at risk of
developing diabetes are detected early [20]. Unfortunately, only 49% of Canadians over 40
years old report ever having a diabetes screening blood test sometime during their life [21]
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and much diabetes and prediabetes remains undiagnosed [10]. Future treatment costs could
possibly be avoided by increasing prevention and screening efforts.
4. Diagnosis of diabetes
This section will outline the many tests possible and the best choices for family physicians.
Prediabetes and diabetes can be diagnosed with inexpensive fasting blood tests [either a fasting
plasma glucose (FPG) level or a 75-gram oral glucose tolerance test (OGTT). The WHO 2006
diagnostic criteria provide the appropriate cut-off points for blood tests interpretation (see
Table 1) [22]. The FPG test is commonly used by Canadian physicians to identify those with
prediabetes and diabetes [21].
Measurement of only a FPG misses 15% or more of people with IGT [23,24]; but, using the
diagnostic criteria for IFG identifies a different and smaller group of people compared to using
criteria for IGT [25,26]. Although the oral glucose tolerance test (OGTT) is the diagnostic gold
standard, cost and impracticality limit its use as a screening test (overnight fasting and a 2-
hour laboratory wait are required). In addition glycosylated hemoglobin or A1c is already
being used as a diagnostic test by many physicians. The American Diabetes Association in
2010 recommended that A1c could be used as a screening test in non-pregnant individuals,
and those without chronic kidney, liver or blood disorders which can all affect the hemoglobin
levels [27]. Their recommendations state that an A1c of 6.5% (47 mmol/mol) or higher indicates
diabetes and an A1c of 5.7% - 6.4% (39 - 46 mmol/mol) is indicative of prediabetes.
The Canadian Diabetes Association has also followed suit and recommended that A1c be used
as a screening tool with the same limitations, and diagnostic for diabetes above 6.5%, however
two separate readings (two of a combination of A1c or FPG) are required for diagnosis [28].
Increasingly, there is debate concerning the use of other laboratory tests since although the
OGTT is the gold standard it may not be used frequently (Ontario data shows that less than
1% of people underwent an OGTT between 1995 and 2005) [29]. An increasing number of
individuals without documented diabetes in Ontario have been tested using the A1c [1].
Additionally, many Ontarians receive serum blood glucose testing, which is either random or
fasting (80% of women and 66% of men) [30].
Fasting Plasma Glucose (mmol/l) 2 hour Post 75g Glucose Load (mmol/l)
T2DM ≥7.0 ≥11.1
Isolated IGT <6.1 7.8-11.0
Isolated IFG 6.1 – 6.9 <7.8
IGT and IFG 6.1 – 6.9 7.8-11.0
Normal <6.1 <7.8
Table 1. Diagnostic Criteria for Diabetes and Prediabetes [22,31,32]
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5. Screening for diabetes
The use of risk assessment tools in general practice will be discussed with reference to the literature.
Though T2DM can often remain undiagnosed and asymptomatic in its early stages [33], once
diagnosed, it can be treated with lifestyle modification and medication, and some elements of
the disease process may be reversible [14,16,34]. In light of this, early T2DM detection may be
beneficial to both patients and society [35]. Screening may also detect people at high risk of
developing diabetes; and thereby, determine the likelihood that a person may have a positive
diagnosis of diabetes.
Screening for diabetes can be approached in 3 different ways; opportunistic, risk-based or
universal. Opportunistic screening occurs where a health care practitioner will screen as part
of routine medical care, whether this is part of a physical examination or other arising medical
interaction [36]. Risk-based screening focuses on screening individuals at high risk of devel‐
oping diabetes due to a health related trait that they have, such as obesity, age, positive family
history [37]. Universal screening would screen everyone irrespective of characteristics [37] or
just use age and gender criteria for screening.
Since the OGTT is the gold standard, including it in any screening program for diabetes and
prediabetes may therefore be an important strategy [37], though impractical for universal
screening. The challenge is how to improve the overall accuracy of diabetes screening, and to
incorporate OGTT at a reasonable cost, by incorporating it as part of a multi-stage screening
process. This two-step approach has already been tested and proven in Finland, and is now
being implemented across many European countries as an emerging best practice. Literature
demonstrates that non-laboratory based questionnaires (e.g. the FINRISK) to pre-identify
individuals at risk of T2DM and prediabetes can be successful [38,39]. Screening questionnaires
have similar diagnostic accuracy to laboratory screening tests and are inexpensive, simple to
use and can also be used as educational tools for patients undergoing screening [38,39,40].
They can be used in conjunction with laboratory testing for universal screening.
An effectively screened population will have diabetes diagnosed 5–6 years earlier than a
population without an organized screening program [41], offering opportunities for delaying
diabetes and related complications [16]. The current screening tests of repeated serum glucose
measurements are too costly and inconvenient to be offered at a population level in the form
of a screening program. Furthermore, the organization of primary care in Canada is poorly
designed to cope with the initiation and management of comprehensive diabetes screening for
everyone over 40 years of age [36]. Existing diabetes prevention and lifestyle programs,
designed for research and not community application, have unrealistic program costs, since
they require all participants to have OGTTs [42,43]. However, sequential and selective
screening of high-risk groups could increase efficiency [44] and reduce workload and screening
costs for the healthcare system by reducing the number of individuals requiring a ‘gold
standard’ diagnostic test, as compared to universal screening [45,46].
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6. Role of family practitioners
This chapter will clarify what the best method of screening is for family physicians by examining the
evidence and provide recommendations for current practice.
In light of the evidence for early treatment of diabetes, in the Canadian Diabetes Association
(CDA) clinical practice guidelines [31,32], the recommendations are clear that individuals at
high risk for developing diabetes should be screened to determine their dysglycemic status,
in an attempt to be able to recommend changes to lifestyle which may prevent or delay the
onset of diabetes. ‘High risk’ is defined as a person whose first degree relatives have diabetes,
and/or who have other diabetes risk factors such as ethnic origin, obesity and dyslipidemia,
and who have a FPG of 5.7-6.9 mmol/L. Though not explicitly stated, the implementation of
this screening recommendation is the responsibility of family doctors, since traditionally they
are the first point of access to health care in Canada. Family doctors usually have the oppor‐
tunity to detect diabetes in their patients at annual health checks as long as the patient has a
physical exam. However, at least 15% of the Canadian population does not have a family doctor
and will not receive a physical examination [47]. Family doctors are a scarce resource and may
not be able to initiate successful screening programs for all their patients. Indeed, evidence
shows that they may be too busy [33], or resources too scarce to implement comprehensive
screening either opportunistically or targeted, or to provide appropriate follow up to identified
individuals. Therefore, opportunistic screening in this way may not be the best approach to
effectively identify the individuals with diabetes. Other strategies may be more appropriate,
but few have been tested or rigorously evaluated in family practice.
Rather than a universal screening program of everybody over the age of 40 years, selective
screening of subgroups at high risk of having the disease may reduce the workload and the
cost to the healthcare system by reducing the number of individuals who need a diagnostic
test [48], while still identifying the vast majority of new cases. Involving patients themselves
in the decision to attend screening may also lessen the burden on family physicians, since a
consultation initiated for risk assessment alone, is likely to be more focused than one initiated
for other reasons [49]. Taking into account these issues, a program utilising this philosophy,
the Community Health Awareness of Diabetes program, was developed and piloted in
Ontario. CHAD assessed risk of diabetes in the over 40 year old population using the Finnish
Diabetes Risk Score [38] (for impaired glucose tolerance detection), the Cambridge Diabetes
Risk Score [50] (for undiagnosed diabetes), fasting capillary blood glucose and a glycosylated
hemoglobin level. Individuals were invited by their family doctors, for ‘diabetes awareness
and risk assessment’ sessions delivered by specially trained community peers, in a network of
local community pharmacies.
There were 588 participants in CHAD; of these, the majority that had received invitation letters
were seniors and were females; 526 did not have pre-existing diabetes; and 16% of participants
were identified as being at high risk for diabetes [51]. Those at high risk of diabetes had
significantly more modifiable risk factors, including higher fat, fast food and salt intake, and
higher systolic blood pressure. Satisfaction with the program was high. An audit of 1030
medical charts of individuals eligible to attend the CHAD program, from 28 family doctors’
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practices in Grimsby, Ontario. Of these, 387 charts were of patients who had attended the
CHAD program and 643 charts were of individuals who did not attend the program but who
met the program eligibility criteria. Overall, the difference between the rates of diabetes
diagnosis before-and-after the program was not statistically different. The difference in rate of
diabetes diagnosis annually in the attendee group was 20 per 1000 and in the non-attendee
group was -2 (to be interpreted as 0) per 1000. In the community, the annual rate of new diabetes
diagnosis was 27 per 1000 (95% CI = 17.90 – 39.00) in the year before the introduction of the
CHAD program, and 45 per 1000 (95% CI = 33.00 – 59.80) in the year after.
The attendee and non-attendee groups were significantly different demographically in that
the CHAD attendees were more likely to be female, retried and older than the random sample
of eligible patients drawn from the same practices. Multi-level regression modeling showed
that attending CHAD did seem to have a positive effect on whether diabetes was diagnosed;
however, this effect was lessened both in statistical significance and magnitude when taking
in to account the physician effect (clustering), patient gender, patient employment status and
patient age. If found to be effective in both case detection and cost, a targeted community
diabetes screening program should be recommended to Canadian Health Policy makers.
Current literature shows that screening is more cost effective in hypertensive and obese groups
and the costs of screening are offset in many groups by lower treatment costs [52].
7. Conclusions
The debate for or against screening and even the method of screening in the community
therefore has not been fully resolved in Canada. Currently, though the Canadian Diabetes
Association recommends screening all individuals over the age of 40 [31,32], the Canadian
Task Force on Preventive Health Care (CTFPHC) recommends screening only for adults with
hypertension or hyperlipidemia [46]. Both guidelines are under frequent review and revision.
For now, health policy makers will need to assess their own communities’ needs, which may
vary based on the population mix, and assess whether or not local programs for screening
(whether targeted or universal) could be initiated; an example of this is the Aboriginal Diabetes
Initiative [53]. Through this program, targeting the Aboriginal population increased regular
screening for early diagnosis using population-based and opportunistic screening methods is
supported, with the use of mobile detection programs. It is possible that diabetes screening
could be increased in communities predicted by population-based algorithms to have high
rates of undiagnosed diabetes [54]. Researchers have used population based data (national
registries and other such data) and developed and validated an algorithm to estimate the
number of individuals who will develop diabetes over a 9-year period [54]. This algorithm
could be applied to existing provincial data to decide where to focus diabetes screening
strategies for greatest effect.
Those reading this chapter from other countries must evaluate the need for screening for
diabetes or at the very least, risk-assessment for diabetes, in the primary care setting, which is
the natural setting for such activities. Given the epidemic of diabetes worldwide, it is likely
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that many other countries will be able to use the case study example posed here, as a way of
evaluating the need to screen in primary care or family medicine situations elsewhere.
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